

Metallomics

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

ApoHRP-based Assay to Measure Intracellular Regulatory Heme

Hani Atamna^{1,2*}, Marmik Brahmhatt¹, Wafa Atamna¹, Gregory A. Shanower¹, and
Joseph M. Dhahbi³

¹Department of Basic Sciences, TCMC, Scranton, PA. ²Department of Medical Education, California Northstate University (CNSU), Elk Grove, CA. ³Department of Biochemistry, University of California at Riverside, Riverside, CA, USA.

Key Words: Heme, Amyloid- β , toxic metal, peroxidase.

Running title: Regulatory heme.

Abbreviations:

RH, Regulatory Heme; HRM, Heme Regulatory Motif; NMP, N-methyl protoporphyrin IX; ALA, δ -Aminolevulinic acid; holoHRP, holo horseradish peroxidase; apoHRP, apo-horseradish peroxidase; heme (ferro-protoporphyrin IX), iron's redox state is Fe^{+2} ; hemin (ferriprotoporphyrin ix), redox state of Fe^{+3} and chloride as a ligand; A β , Amyloid- β \square Pb, Lead; Hg, Mercury.

* Correspondence;

Hani Atamna

hani.atamna@cnsu.edu

Address for Proofs:

Hani Atamna

Department of Medical Education

California Northstate University

9700 West Taron Drive

Elk Grove, CA. 95757

Abstract:

The majority of the heme-binding proteins possess a “heme-pocket” that stably binds with heme. Usually known as housekeeping heme-proteins, they participate in a variety of metabolic reactions (e.g., catalase). Heme also binds with lower affinity to the “Heme-Regulatory Motifs” (HRM) in specific regulatory proteins. This type of heme binding is known as exchangeable or regulatory heme (RH). Heme binding to HRM proteins regulates their function (e.g., Bach1). Although there are well-established methods for assaying total cellular heme (e.g., heme-proteins plus RH), currently there is no method available for measuring RH independently from the total heme (TH). The current study describes and validates a new method to measure intracellular RH. The method is based on the reconstitution of apo-horseradish peroxidase (apoHRP) with heme to form holoHRP. The resulting holoHRP activity is then measured with a colorimetric substrate. The results show that apoHRP specifically binds RH but not with heme from housekeeping heme-proteins. The RH assay detects intracellular RH. Furthermore, using conditions that create positive (hemin) or negative (N-methyl protoporphyrin IX) controls for heme in normal human fibroblasts (IMR90), the RH assay shows that RH is dynamic and independent from TH. We also demonstrated that short-term exposure to subcytotoxic concentrations of lead (Pb), mercury (Hg), or amyloid- β (A β) significantly alters intracellular RH with little effect on TH. In conclusion the RH assay is an effective assay to investigate intracellular RH concentration and demonstrates that RH represents ~6% of total heme in IMR90 cells.

Introduction:

Heme is a prosthetic group that binds tightly with the heme-pocket in many of “housekeeping” heme-proteins in both prokaryotic and eukaryotic cells (e.g., catalase, cytochromes)¹. Housekeeping heme-proteins are essential for cellular function due to their ability to catalyze specific biochemical reactions^{2,3}. These housekeeping heme-proteins can bind heme irreversibly by covalent bond (e.g., cytochrome c) or non-covalently (e.g., cytochrome b). When non-covalently bound, heme affinity to the apoprotein is usually very high (K_d ranges between 10^{-12} - 10^{-15} M), indicating that the heme moiety is mostly protein-bound. Interestingly, exchange of heme moiety can occur when a heme-protein is interacting with an other protein that exhibits a higher affinity for heme⁴.

In addition to the housekeeping function, a role for heme as a regulator for specific proteins (heme-responsive proteins) is emerging^{1, 5}. For example, heme regulates its own synthesis as well as several additional biological functions^{5a}. In this role heme can regulate specific proteins by binding in an ON/OFF mechanism to Heme Regulatory Motif (HRM) in specific proteins^{5a, 6}. Contrary to heme in housekeeping heme-proteins, HRM-dependent proteins reversibly bind with Regulatory Heme^{5a, 6b, 7}. Miksanova et al. showed that the binding of RH to HRM is weaker than heme binding with the heme-pocket in heme-proteins^{7b}. An additional type of regulation by heme involves changes to heme ligation status (e.g., binding NO) or by altering the redox status of heme-iron in specific heme-proteins⁵⁻⁶.

The source of heme in the HRM-dependent type of regulation is believed to originate from “free heme”, “exchangeable” heme (from low affinity heme-binding proteins), or newly synthesized heme, which collectively we will refer to as Regulatory Heme (RH). Furthermore, the biophysical nature of RH has not been established^{6a, b, 7a, 8}. Regardless of being “free” or “exchangeable”, several lines of evidence demonstrate the transient effect of heme on the activity of specific HRM-dependent protein factors, which is consistent with a regulatory role^{6a, b, 7a, b, 8-9}. The HRM-dependent proteins include the heme activator protein (Hap1)¹⁰, δ -aminolevulinic acid synthase (ALAS)¹¹, iron regulatory protein-2 (IRP2)¹², heme-regulated eukaryotic initiation factor 2 (eIF2) kinase (HRI) (protein translation)¹³, DGCR8 (RNA processing)¹⁴, REV-erb- α ⁹, and the transcriptional repressor Bach1¹⁵. In general, the interaction of heme with these proteins influences regulatory steps of the cellular metabolism rather than providing a direct catalytic

1
2
3 activity. For example, RH regulates its own synthesis by controlling ALAS import into the
4 mitochondria, which is the rate-limiting enzyme of heme synthesis ¹¹.
5
6

7 The current study is concentrating on Regulatory Heme. RH has not been directly
8 investigated in cells due to the lack of a specific method for measuring RH independently from
9 heme moiety of the housekeeping heme-proteins ¹⁶. Most of our knowledge about RH comes
10 from indirect observations of protein factors that transiently bind heme. For example, Sassa et. al
11 has proposed that the intracellular RH concentration is in the range of low nM ¹⁶. Therefore, we
12 adapted and modified a method for the determination of free heme in chloroplasts, which
13 involves extraction with organic solvents¹⁷, to develop an assay to measure cellular RH. The
14 purpose of the current study is to provide a simple assay to measure intracellular RH (RH assay)
15 independently from the heme moiety of the housekeeping heme-proteins, which accounts for the
16 majority of the total heme.
17
18

19 The RH assay is described in details in the following sections. In order to validate the
20 method we performed control experiments as well as examined the effect of specific treatments
21 that are known to alter the intracellular level of heme and used these treatments to create
22 conditions of positive or negative controls in human lung fibroblasts (IMR90). Then, we used the
23 RH assay to investigate the susceptibility of RH to Pb and Hg as well as to amyloid- β (A β).
24 These agents are known to interfere with heme metabolism. The RH assay provides accurate and
25 quantitative information about the intracellular concentration of RH, which may facilitate future
26 investigations into RH in different cell types and tissues.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Methods:

Materials: Pb(NO₃)₂, Hg(NO₃)₂, HNO₃, human hemoglobin, catalase, and sodium dithionite were obtained from Sigma (St. Louis, MO). Amyloid-β₄₀ (Aβ) was from American Peptides Company (Sunnyvale, CA). ApoHRP was from Calzyme Labs (San Luis Obispo, CA). Hemin and N-methyl protoporphyrin IX (NMP) were from Frontier Scientific (Logan, UT). Peroxidase Substrate Kit TMB (SK-4400) was from Vector Labs (Burlingame, CA). Bio-Gel P2 gel filtration beads were from Bio-Rad (Hercules, CA). Protease inhibitors cocktail was from MP Biomedicals (Solon, OH). DNase, RNase, and protease free TritonX100 was from ACROS Organics (Pittsburgh, PA) and all the organic solvents were HPLC grade (Fisher Scientific). Normal human lung fibroblasts (IMR90) were from Coriell Institute for medical research (Camden, NJ). Cell culture media and reagents (DMEM, FBS, Pen/Strep, and trypsin-EDTA (0.05% trypsin/0.53 mM EDTA) were from Life-Technologies.

IMR90 cell culture preparation and cell counting: IMR90 cell were seeded at 0.5 million cells per plate in 10 ml DMEM supplemented with 10 % fetal bovine serum (FBS) and 2 ml Penicillin and Streptomycin (Pen/Strep). The cells were harvested with 1.5 ml trypsin/EDTA and counted using Beckman-Coulter Z2 (Brea, CA) for particle count and size analysis¹⁸. The cells were collected by centrifugation at 4 °C and used for lysate preparation or stored at -80 °C.

Cell lysate preparation and protein quantification: The lysates from 5-7 million IMR90 cells were prepared in 300 μl of ice-cold PBS/0.1% Triton-X100 supplemented with 20 μl of protease inhibitors. The lysates were then sonicated and centrifuged at 18000 xg for five minutes at 4 °C. The protein content of the lysate was determined using Quick Start Bradford Dye Reagent (Bio-Rad, Hercules CA) and fatty acid free Bovine Serum Albumin. This lysate preparation produces a protein concentration of about 2-3 μg/μl.

Stock solution of hemin: Hemin stock solution was freshly prepared by dissolving 3.27 mg into 5 ml 0.1 N NaOH and stored in dark. The solution was centrifuged to remove insoluble material and the concentration was determined from the absorbance at 385 nm and the mM extinction coefficient of 58.4 using spectrophotometer DU800 (Beckman Coulter, Brea, CA).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Preparing stock solution of ApoHRP: The commercial apoHRP was extracted by acid acetone solution¹⁹ (250 μ l concentrated HCl (36%) in 10 ml acetone) in order to eliminate any possible residual HRP activity. Briefly, 8 mg apoHRP were dissolved in 2 ml DDW and extracted with 40 ml acid acetone. The pellet was then collected by centrifugation at 2000xg for 2 min, and dissolved in 2 ml PBS. The residual HRP activity was measured by the peroxidase TMB assay kit. The cycle of extraction can be repeated if necessary. The concentration of apoHRP was confirmed using a molar extinction coefficient at 280 nm of 20,000²⁰. A stock of 50 μ M apoHRP was prepared in PBS and saved in aliquots at -20 °C.

HPLC analysis for total cellular heme: The total heme (TH) of cellular lysates, which includes both heme in heme-proteins (except heme *c*) and RH, was extracted with acid acetone (250 μ l concentrated HCl in 10 ml acetone) and measured as described earlier²¹. Hemin from the working solution of 10 nM was similarly extracted with acid acetone and used as HPLC standard. Fifteen microliters of each sample and the standard were injected into an ODS Hypersil (C18) 250x4 mm column (particle size 5 μ m) and separated with a gradient of two mobile phases using Waters Binary HPLC Pump-1525; Waters 2489UV/Vis detectors; Waters 2707 autosampler with temperature control; and Empower-Pro software control and data analysis. Hemin separation was accomplished at room temperature by utilizing a gradient made by mixing the two mobile phases A and B. Mobile Phase A: was made from 30% acetonitrile; 70% DDW; and 0.05 % heptafluorobutyric acid (HFBA), Mobile Phase B: was made from 85% Acetonitrile; 15% DDW; and 0.05 % HFBA. The separation cycle was 39 min and depended on two mobile phases as follows: 2 min wash with 100% mobile phase A; within 22 min switch to 100% mobile phase B; maintain 100% mobile phase B for 2 min; within 5 min switch to 100% mobile phase A; maintain 100 % mobile phase A for 8 min. Heme elution was monitored at 398 nm.

The assay for Horseradish Peroxidase (HRP): The Peroxidase Substrate TMB kit for measuring peroxidase activity depends on the oxidation of 3,3',5,5'-tetramethylbenzidine (TMB)²². The oxidation of TMB by holoHRP was measured at 652 nm with the plate reader SpectraMax M5 (Molecular Devices, Sunnyvale, CA).

Establishing the standard curve of ApoHRP reconstitution with hemin (RH assay): The stock

1
2
3 solution of hemin was diluted in DDW to 25 nM, which was immediately used for the regulatory
4 heme assay. The apoHRP working solution of 50 μ M was also freshly prepared in PBS or from
5 frozen aliquot. The time-dependence of apoHRP reconstitution with hemin was determined by
6 mixing 10 μ l apoHRP (final concentration 5 μ M) with 10 μ l hemin (final concentration 2.5 nM)
7 in a tube that already contains 80 μ l PBS followed by incubation at 4 °C. The final volume of the
8 reconstitution reaction was 100 μ l. (The 5 μ M apoHRP were determined in a separate experiment
9 that is described in the following section). At different intervals a 10 μ l aliquot was removed
10 from the reconstitution reaction and used to measure the resulting holoHRP activity with the
11 TMB peroxidase substrate kit. The holoHRP activity, presented as absorbance at 652 nm, was
12 then plotted against the reconstitution time (min). This experiment establishes the minimal time
13 that is required for apoHRP to reconstitute with hemin.
14
15

16
17
18
19
20
21
22
23 A hemin standard curve was then prepared as follows and as summarized in Table 1. A
24 10 μ l of 50 μ M apoHRP were added to each one of pre labeled seven Eppendorf tubes followed
25 by adding increasing concentrations of hemin using the 25 nM hemin solution to give the
26 following final concentrations: 0, 0.25, 0.5, 1, 1.5, 2, 2.5 nM (i.e., 0, 25, 50, 100, 150, 200, 250
27 fmole) after bringing the final volume in each tube to 100 μ l with PBS as described in Table 1.
28 The reconstitution reactions were then mixed and incubated for at least ten minutes in 4 °C. At
29 the end of the incubation, the holoHRP activity was measured by transferring 10 μ l out of each
30 reconstitution reaction to 96-well plate wells followed by 200 μ l of TMB working solution using.
31 The enzymatic oxidation of TMB was allowed to progress for 5-10 min (or as needed). The
32 absorbance was read using a plate reader (SpectraMax M5, Molecular Devices) set at 652 nm.
33 The absorbance data at 652 nm was plotted against the fmole of hemin in each well to establish
34 the standard curve. The final concentration of apoHRP in each of the seven tubes is 5 μ M (i.e.,
35 500 pmole). Thus, the ratio of apoHRP to hemin at each concentration of hemin is 2×10^4 , 1×10^4 ,
36 5×10^3 , 3.3×10^3 , 2.5×10^3 , and 2×10^3 , respectively (Table 1). It is important to indicate that PBS
37 can be replaced with 80 mM KCl; 20 mM sodium phosphate, and 20 mM HEPES at a pH 7.
38 Furthermore, the hemin working solution can be prepared in 50% DMSO. Although we found
39 that both buffers work equally well, the data we present was collected using PBS and DDW.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

55 ***Measuring RH in cellular lysate using the RH assay:*** The procedure of RH quantification using
56 cellular lysate was identical to the procedure of preparing the standard curve, except that hemin
57
58
59
60

1
2
3 was replaced with cellular lysate as summarized in Table 1 and presented here in more details.
4
5 To Eppendorf tubes a 25 μ l of PBS were added followed by 10 μ l of 50 μ M apoHRP and 10 μ g
6 of protein from the lysate (usually 3-5 μ l of the lysate). (The 10 μ g apoHRP were determined in
7 a separate experiment that is described in the following section). The final volume of the
8 reconstitution reaction is then brought to 100 μ l with PBS (Table 1). After mixing, the
9 reconstitution reaction was incubated for at least ten minutes at 4 $^{\circ}$ C. At the end of the
10 incubation, the activity of holoHRP was measured as described previously. Briefly, up to 30 μ l
11 (3 μ g protein) were transferred from each of the 100 μ l reconstitution reactions to separate wells
12 of a 96-well plate followed by transferring 200 μ l of TMB working solution using a multi
13 channel pipette. The absorbance was measured using plate reader set at 652 nm (SpectraMax
14 M5, Molecular Devices). The RH in the lysate sample was calculated with the help of a standard
15 curve that was simultaneously prepared as described in the previous section (Figure 1B) and
16 normalized to 1 mg protein. The development time of holoHRP activity depends on the RH
17 concentration in the sample and is usually 5-10 min. Regardless of the precise development time
18 of holoHRP assay, it is important that both the standard curve and the lysate samples be allowed
19 to develop simultaneously for the same duration. The contribution of the lysate the absorbance
20 at 652 nm (i.e., background) was measured by simulating the reconstitution reaction while
21 omitting apoHRP (Table 1 note 5). This contribution is usually close to zero, however, it is
22 important to subtract the background from the signal.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 ***Determining the optimal concentrations of apoHRP and protein lysate for the RH assay:*** The
40 concentration of apoHRP that is required for optimal reconstitution with lysate was determined
41 by using increasing concentrations of apoHRP. Each of the apoHRP concentrations was mixed
42 with 10 μ g of the lysate protein and incubated for 10 min. The procedure was identical to that of
43 the RH assay as described in table 1, except that the increase in the volume of apoHRP was
44 accounted for by similar decrease in the volume of PBS.
45
46
47
48

49 The linearity of the RH assay with increasing protein was examined by mixing 5 μ M
50 apoHRP with increasing concentrations of protein lysate. The rest of the assay was performed as
51 described in table 1, except that the increase in the volume of the lysate was accounted for by
52 similar decrease in the volume of PBS. The activity of holoHRP that result from the
53
54
55
56
57
58
59
60

1
2
3 reconstitution of apoHRP in both experiments was plotted against the concentration of apoHRP
4 or the concentration of the protein, respectively.
5
6
7

8
9 ***Examining the specificity of ApoHRP towards regulatory heme:*** Catalase and hemoglobin (Hb)
10 are two typical heme-proteins that bind heme tightly in an almost irreversible manner.
11 Furthermore, these are typical heme-proteins that have had their binding properties extensively
12 studied and binding constants clearly determined. Thus, in order to test if apoHRP is capable of
13 removing heme that is already complexed with heme-proteins, we substituted hemin in the RH
14 assay with either catalase or hemoglobin. Stock solutions of catalase or hemoglobin were
15 prepared in PBS and then purified by gel filtration using Bio-Gel P2 beads in order to remove
16 possible unbound (exchangeable) heme contamination, which is usually found in commercially
17 prepared heme-proteins. The concentration of hemoglobin and catalase were calculated using the
18 extinction coefficients ($\text{mM}^{-1} \text{cm}^{-1}$) of 524 at 415 nm for Hb²³ and of 290 at 405 nm for catalase
19²⁴. Hb and catalase were used at a final concentration of 60 nM each.
20
21
22
23
24
25
26
27

28 Commercial Hb is essentially auto-oxidized to methemoglobin (metHb), which has lower
29 affinity for heme²⁵. MetHb can be reduced to Hb with sodium dithionite. Thus, we decided to
30 compare heme transfer to apoHRP from Hb-O₂ that was or was not reduced by sodium
31 dithionite. MetHb was reduced by adding few grains of sodium dithionite to the stock solution of
32 50 μM metHB. The reduction of metHb in open air forms Hb-O₂, which was determined by the
33 red-shift of the Soret band (from 406 to 412 nm) and the appearance of a 543 nm and 577 nm
34 peak (data not shown). We then used these preparations to compare the ability of apoHRP to
35 extract heme moiety from Hb-O₂ and metHb (i.e., before and after reduction with sodium
36 dithionite), or catalase. The procedure was the same as for the RH assay as described in table 1,
37 except that the lysate was substituted with Hb-O₂, metHb, or catalase. The reconstitution reaction
38 with each of the heme proteins (Hb-O₂, metHb, or catalase) was allowed to proceed for different
39 time points. At each time point a sample of the reconstitution reaction was removed and used to
40 measure the resulting holoHRP with the TMB peroxidase assay kit. The holoHRP activity was
41 plotted against the reconstitution time. The potential interference of sodium dithionite with the
42 peroxidase assay was examined by adding few grains of dithionite to PBS (without metHb).
43 Then we diluted the dithionite solution 833 times (simulating the dilution from 50 μM to 60 nM)
44 and incubated in ice until it is tested with the TMB assay kit (mimicking the steps of the RH
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

assay). A sample from this preparation was tested for its effect on holoperoxidase activity using the TMB assay kit. Holoperoxidase was prepared separately using hemin as described in table 1.

Furthermore, in order to examine if heme moieties from the many heme-proteins that are native to the lysate would transfer to apoHRP, the reconstitution reaction between the lysate (10 μg protein) and apoHRP was extended beyond 2 min. The reconstitution reaction was allowed to proceed for various intervals and at the completion of each reconstitution time point the resulting holoHRP activity was measured and the activity was plotted against the reconstitution time.

The effect of positive and negative controls on intracellular RH: Inhibition of heme synthesis by N-methyl protoporphyrin IX (NMP), a specific inhibitor of heme synthesis ²⁶, is expected to lower RH (negative control) while adding hemin to the growth medium is expected to increase RH (positive control). For the negative control, IMR90 cell culture was incubated up to 72 hours with 8 μM NMP. At each time point the cells were harvested and prepared for measuring total heme and RH. NMP has no cytotoxicity at the conditions used in this experiments ²⁷. For the positive control of RH, increasing concentrations of hemin were added to the growth medium of IMR90 cells for 45 min. At the end of the incubation, the medium was removed, each culture was washed with ice-cold PBS, and the cells were harvested, and pelleted by centrifugation. The cells were washed again three times with PBS, and stored at $-80\text{ }^{\circ}\text{C}$ until use.

The effect of Hg, Pb, and Amyloid- β ($A\beta$) on intracellular RH: Hg and Pb are known to interfere with heme synthesis ²⁸, thus we tested their effect on RH. Hg and Pb were dissolved in HNO_3 at 3 mM stock solutions. The cultures of IMR90 cells were incubated with increasing concentrations of Hg, Pb, and HNO_3 for 24 hr. The concentrations of Hg were: 0.5, 50, 500, and 5000 nM while the concentrations of Pb were: 250, 500, 750, and 1000 nM. After 24 hr the cultures were harvested and the cells were stored at $-80\text{ }^{\circ}\text{C}$ until use. The lysates were prepared and RH and total heme were determined using the RH assay and HPLC, respectively. The effect of the vehicle HNO_3 on RH was similarly examined using the respective concentrations of HNO_3 to which the cells were exposed when treated with Pb or Hg (ranged from 22.4 nM to 44.8 μM).

$A\beta_{40}$ peptide binds heme tightly and interferes with heme synthesis ²⁸. $A\beta_{40}$ was dissolved in NANOpure water to give a final concentration of 300 μM and stored as aliquots in $-80\text{ }^{\circ}\text{C}$. IMR90 cell cultures were treated with 500 nM $A\beta$ for up to 24 hr. At different time

1
2
3 points, the cultures were harvested and the cells were stored at -80 °C until use. The lysates were
4 prepared as above followed by determining RH and total heme as described above.
5
6
7

8
9 ***Statistical analysis:*** Graphing and statistical analysis using *t*-tests, Mann-Whitney
10 nonparametric tests, or one-way ANOVA were performed using Prism 6.0 software (GraphPad,
11 San Diego, CA, USA). Significance was defined at 95% confidence interval when $P < 0.05$.
12 Prism 6.0 software (GraphPad, San Diego, CA, USA) was also used for linear and non-linear
13 regression analysis of the data sets using equations built in Prism 6.0.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results:***Establishing the standard curve for the RH assay utilizing the reconstitution of ApoHRP with hemin to form active HoloHRP:***

The time-dependent reconstitution of hemin with apoHRP to form holoHRP is shown in figure 1A. The reconstitution reaction reached plateau within 2 min and the resulting holoHRP activity remained constant until the end of the experiment, indicating the stability of holoHRP. We estimated that 10 min was sufficient to bind all the free hemin in the solution and to complete the formation of holoHRP. We then examined if the reconstitution of apoHRP with increasing concentrations of hemin correlates with the formation of holoHRP activity (Table 1). A linear correlation between hemin concentration and holoHRP activity is shown in figure 1B, which established the standard curve for hemin. The data from the standard curve showed that the apoHRP-heme reconstitution assay (RH assay) could detect low femtomole levels of hemin. The limit of detection (LD) of the RH assay was 0.13 ± 0.06 fmole/200 μ l (0.65 ± 0.3 pM) and the quantification limit was 0.4 ± 0.2 fmole/200 μ l (2 ± 1 pM). Precision and accuracy were determined by calculating the relative standard deviation (RSD) as 6 ± 1.5 %.

The majority of the hemin in aqueous solutions is in the form of dimers, which is in equilibrium with monomers²⁹, raising the question whether the dimer form of hemin interferes with the reconstitution reaction. Thus, the efficiency of the reconstitution step was evaluated under conditions where hemin was prepared in an aqueous solution (which forms mainly dimers) or in 50 % DMSO (which forms mainly monomers). The standard curves were very similar regardless if the working solution of hemin was prepared in PBS or 50% DMSO. A sample of fitting equations of the linear regression for the standard curves data were $y=0.059*x+0.13$ ($R^2=0.985$) and $y=0.062*x+0.128$ ($R^2=0.99$) for PBS and 50% DMSO, respectively. A likely explanation for the high efficiency of apoHRP's reconstitution with hemin in PBS is that hemin dimers dissociate into monomers²⁹, a process that could be enhanced by the high ratio of apoHRP (5 μ M) to hemin (Table 1). ApoHRP can further drive the dissociation of hemin dimers by the high stability of holoHRP, which prevents the dissociation of heme from holoHRP.

ApoHRP reconstituted with hemin and RH but not with heme moiety from housekeeping heme-proteins:

1
2
3 The cellular milieu contains housekeeping heme-proteins in addition to exchangeable or
4 regulatory heme (RH). Thus, the possibility that heme may transfer from a housekeeping heme-
5 protein to apoHRP was tested using catalase, hemoglobin, metHb as well as heme proteins native
6 to the cellular lysate.
7
8
9

10 There was a transfer of heme from Hb-O₂ to apoHRP when apoHRP (5 μM) was
11 incubated with Hb-O₂ (60 nM) in the absence of sodium dithionite. This was evident in the
12 continued formation of holoHRP with time (Figure 2A, – sodium dithionite). This transfer of
13 heme to apoHRP was probably due to the fact that the commercial Hb is oxidized to metHb (Hb
14 with oxidized heme-iron), which binds heme at lower affinity than Hb. Thus, heme from metHb
15 transfers to apoHRP, albeit at very slow rate as seen in figure 2A (– sodium dithionite) after 2
16 min of incubation. Sodium dithionite reduces heme-iron and converts metHb to Hb-O₂ (in the
17 presence of O₂), which binds the heme moiety at higher affinity than metHb (see Discussion).
18 Interestingly, contrary to metHb there was no transfer of heme from Hb-O₂ to apoHRP (Figure
19 2A, + sodium dithionite). Additionally, there was no time-dependent increase in the
20 reconstitution of apoHRP with Hb-O₂ after 2 min (Figure 2A, + sodium dithionite). These
21 observations demonstrated that apoHRP did not extract heme from Hb-O₂, the normal form of
22 Hb *in vivo*.
23
24
25
26
27
28
29
30
31
32

33 Incubating apoHRP with catalase (a different heme-protein) showed negligible formation
34 of peroxidase activity, which did not develop further with increasing incubation time (Figure
35 2B). The small burst of holoHRP activity that was seen at the 2 min in figures 2B and 2A could
36 be the result of a small amount of hemin that remained after gel filtration.
37
38
39

40 In addition to Hb and catalase, we examined the ability of apoHRP to extract the heme
41 moiety of the housekeeping heme-proteins native to the lysate. Consistent with the results from
42 figure 1A, the reconstitution of apoHRP with RH from the lysate was complete within 2 min
43 (Figure 2C). Furthermore, similar to Hb or catalase, extended incubation of apoHRP with the
44 lysate did not cause additional formation of holoHRP (Figure 2C). Taken together, these
45 observations indicate that apoHRP was unable to extract heme from the heme-proteins of the
46 lysate, Hb, or catalase and supports the conclusion that apoHRP-based RH assay specifically
47 reconstitutes with RH or exchangeable heme (as the case in metHb) and not with heme moiety of
48 housekeeping heme-proteins. We estimated that 10 min would be sufficient to bind all the RH or
49 exchangeable heme to form holoHRP.
50
51
52
53
54
55
56
57
58
59
60

Determining the optimal concentrations of apoHRP and protein lysate for the RH assay:

The concentration of apoHRP for the optimal reconstitution reaction was determined by plotting the dose-response of apoHRP concentration against holoHRP activity using 10 μg protein lysate (Figure 3A). The plot showed that holoHRP formation reached plateau at 5-6 μM apoHRP. Thus, the concentration of apoHRP for reconstitution with hemin or with lysate was set at 5 μM . We also determined the optimal concentration of the lysate protein for the RH assay. The RH assay was linear with increasing concentration of the lysate proteins (Figure 3B). Linear regression analysis for the relation between RH and protein (μg) produced the linear equation: $Y=3.9*X+16.4$ ($R^2=0.95$). Thus, the concentration of protein lysate between 5-60 μg in the reconstitution reaction was optimal for the RH assay.

The RH assay detected changes to intracellular regulatory heme:

The data from the controls of several experiments were used to calculate the averages of RH and total heme in IMR90 cells. The average of RH in IMR90 cells was found to be 4.3 ± 1.5 pmol RH/mg protein (mean \pm SD), while that of total heme was found to be 67 ± 15 pmol/mg protein (mean \pm SD, Table 2). These averages were used to calculate the percent of RH out of the total extractable heme, which was found to be $\approx 6\%$ (Table 2). Furthermore, we used the RH values in conjunction with the cell volume of human fibroblasts to calculate the intracellular concentration of RH. The cell volume of human fibroblasts was reported to be about 2500 fl³⁰, which we confirmed by directly measuring IMR90 cell volume using the Beckman-Coulter Z2. We also found that on average four million IMR90 cells contain 1 mg protein (data not shown). Therefore, RH in IMR90 cells can be presented as 4.3 ± 1.5 pmols RH / 4 million cells. Thus, the average volume of four million IMR90 cells is $\approx 10 \mu\text{l}$ ($2500 \text{ fl} \times 4 \times 10^6 \text{ cells}$). Using 4.3 ± 1.5 pmol RH, the total cell volume of 1 mg protein (i.e., 10 μl protein volume), and that 0.7 is the water fraction of a living cell³¹, we calculated the concentration of RH as follows: (pmole RH) \div (10 μl) \div (0.7). Using the previous equation, the concentration of RH in IMR90 is 614 ± 214 nM (mean \pm SD). The intracellular concentration of RH in IMR90 cells is about 20 times higher than that was previously proposed^{6a, b, 7a, 8 16}. Future investigations that include additional cell types as well as *in vivo* experiments will expand our current understanding of RH homeostasis under physiologic and pathologic conditions and could provide insight regarding its biological significance.

1
2
3
4
5 ***The effect of hemin and heme synthesis inhibitors on intracellular regulatory heme:***
6

7 The effect of inhibiting heme synthesis by NMP on RH was used as a negative control to
8 examine the specificity of the RH assay. The cells were harvested, proteins were measured, and
9 RH assay was performed as described in Table 1. NMP did not affect total heme as measured by
10 HPLC (Figure 4A). However, there was an insignificant decline in total heme after an hour of
11 treatment with NMP. The level of total heme remained stable afterwards. At this time we do not
12 have explanation for this brief effect of NMP. However, within 10 hours of exposure to NMP a
13 significant 29 % decline in RH is observed, which advanced to 71 % decline within the next 24
14 hr (Figure 4B). No further decline in RH was observed in extended incubation time with NMP.
15

16 The effect of adding hemin to the growth medium on RH was used as a positive control.
17 IMR90 cell cultures were incubated with increasing concentrations of hemin (0 to 6 μM). After
18 45 minutes of incubation, excess extracellular hemin was thoroughly washed, and RH was
19 measured using the RH assay. Extracellular hemin caused a significant 3 pmol/mg protein
20 increase in RH, which reached plateau at 2 μM extracellular hemin (20 nmols hemin/10 ml)
21 (Figure 4C). Thus, after adding hemin to the extracellular medium RH level in IMR90 cells was
22 more than doubled.
23
24
25
26
27
28
29
30
31
32

33
34
35 ***Lead (Pb) and mercury (Hg) lower intracellular concentration of regulatory heme:***
36

37 Heme synthesis is subject to interference by variety of exogenous toxic agents such as Pb
38 or Hg. IMR90 cell cultures were incubated for 24 hr with increasing concentrations of Pb or Hg
39 followed by measuring total heme-proteins and RH. Pb and Hg exhibited only a weak effect on
40 total heme-proteins that was not significant (Figure 5A and 5C, respectively). However, the RH
41 level significantly declined by 26%, 34%, and 40% after 24 hr at concentrations of 750, 1000,
42 and 5000 nM of Pb, respectively (Figure 5B). Similarly, Hg caused a 20-23% decline in RH at
43 concentration higher than 500 nM (Figure 5D).
44
45
46
47
48

49 Pb and Hg where dissolved in HNO_3 . As a result the final concentration of HNO_3 that the
50 cells were exposed to ranged from 22.4 nM to 44.8 μM . Thus, the effect of HNO_3 on RH was
51 tested using these concentrations and compared to the control cells. HNO_3 did not affect RH in
52 IMR90 cells (Data not shown).
53
54
55

56 ***Amyloid- β ($A\beta$) peptide lowers intracellular concentration of regulatory heme:***
57
58
59
60

1
2
3
4 Amyloid- β peptide ($A\beta$) forms a complex with hemin *in vitro* ^{21, 28a}. $A\beta$ induces heme
5 synthesis probably due to its ability to bind heme ^{28a}. Thus, it has been presumed that RH is the
6 target of $A\beta$, which could explain the induction of heme synthesis and iron uptake by $A\beta$ ^{28a}.
7 However, there was no experimental evidence to support that $A\beta$ binds with RH. $A\beta$ peptide is
8 formed inside the cell ³² and it also readily penetrates the cell membrane from extracellular
9 sources ³³. Therefore, we tested if $A\beta$ affects the level of RH in IMR90 cells. IMR90 cells were
10 incubated with 500 nM $A\beta$ for various intervals. The level of RH significantly declined by 35%,
11 50%, and 60% after 2, 7, and 24 hr incubation with $A\beta$, respectively (Figure 6A). Total heme-
12 proteins, on the other hand, were not affected by the $A\beta$ peptide (Figure 6B).
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion:

Heme is a prosthetic group that exhibits a regulatory function^{6a, b, 7a, 8}. In general, the fraction of regulatory heme (RH) is referred to as RH, “free heme”, newly synthesized heme, or “exchangeable” heme⁶. In this study we described a quantitative assay for RH that is based on the reconstitution of RH with apoHRP to form holoHRP (Table 1 and Figure 1A). The kinetic of apoHRP reconstitution with hemin shows that the formation of holoHRP is complete within 2 min (Figure 1A, 2C). However, we chose the reconstitution time with apoHRP and lysate to be at least 10 min to ensure complete reconstitution.

The specificity of the RH assay was examined by measuring the transfer of the heme moiety of metHb, Hb-O₂, or catalase to apoHRP. There was no transfer of the heme moiety of the housekeeping heme-proteins (Hb-O₂, catalase, or heme-proteins native to the lysate) to apoHRP (Figure 2A, B, C). These findings demonstrate that apoHRP selectively and specifically reconstitutes only with exchangeable heme and “free heme”. These observations are consistent with that equilibrium dissociation constants (K_d) of heme binding with the heme-pocket of heme-proteins (ranges between 10^{-12} - 10^{-15} M (pM–fM)³⁴), which is much lower than the K_d of apoHRP (estimated to be 15.5×10^{-8} M³⁵). MetHb is formed from oxidation of heme-iron (Fe^{+2}) to heme-iron (Fe^{+3}) in red blood cells or *in vitro*. MetHb, as opposed to Hb-O₂, has a low affinity for heme²⁵, thus explaining the transfer of heme from metHb to apoHRP (Figure 2A). However, when Fe^{+3} in metHb was reduced to Fe^{+2} by sodium dithionite, which increases heme affinity to globin²⁵, heme transfer to apoHRP is eliminated (Figure 2A, open circles). The differential reconstitution of apoHRP with metHb and Hb-O₂ demonstrates that the RH assay measures free heme or/and exchangeable heme that weakly bound with specific heme-proteins.

The concentration of Hb or catalase (60 nM) that we used in figure 2 mimics the concentration of heme-proteins in the lysate. This concentration was calculated based on the HPLC data that show total heme in the lysate is 67 ± 15 pmol /mg protein. In the RH assay we used 10 μ g protein, which contains 0.67 pmol heme proteins in 100 μ l final volume. Thus, the heme concentration is 67 nM. We selected 60 nM of catalase and Hb to examine if heme transfers from heme-proteins to apoHRP, creating similar ratios of apoHRP to: Hb, catalase, or lysate.

Furthermore, we have also examined if the heme moiety from heme-proteins that are native to the whole lysate transfers to apoHRP (Figure 2C). The reconstitution of apoHRP with

1
2
3 heme from native heme-proteins in the lysate is fast and found to be complete within 2 min,
4 which is consistent with the idea that apoHRP binds only with RH (Figure 2C). Importantly,
5 extending the incubation time of apoHRP with the lysate does not lead to additional formation of
6 holoHRP beyond that formed during the first two min. This observation indicates that the heme
7 moiety from the native heme-proteins of the lysate does not transfer to apoHRP (Figures 2C and
8 Figure 3). In conclusion, apoHRP is unable to remove heme from Hb, catalase, or heme-proteins
9 from the lysate. These observations demonstrate that apoHRP binds with RH independently from
10 heme of the heme-proteins. Furthermore, these observations provide support that the fraction of
11 RH (or exchangeable heme) is different from the heme moiety of the heme-proteins; however,
12 the biophysical nature of the RH fraction is under investigation.
13
14
15
16
17
18
19
20

21 Following the validation of the assay, we investigated the effects of various conditions on
22 RH including: hemin, NMP, Hg, Pb, and A□□□□□□□□□□. Using the RH assay we showed
23 that the level of RH in control cells is 4.3 ± 1.5 pmol/mg protein in IMR90 cells (Table 2), while
24 HPLC showed that total heme is 67 ± 15 pmol/mg protein. The variability in RH and total heme
25 that we found could be explained, in part, by the fact that IMR90 cells in tissue culture progress
26 toward senescence. Furthermore, a new IMR90 cell culture must be prepared once the cells
27 senesce. These factors, in conjunction with the typical variability in cell culture preparations,
28 might have contributed to the variation in RH. Taking into consideration the fraction of total
29 heme-proteins, we found RH to be 6 % of total heme. Since heme is a pro-oxidant that can
30 catalyze a Fenton-like reaction producing highly reactive oxygen species that may cause
31 oxidative damage, the steady-state concentration of RH is likely to be maintained under tight
32 balance. Possible factors that contribute to the RH level include the rate of heme synthesis, the
33 level of expression of heme-proteins, heme export (e.g., FLVCR)³⁶, and heme oxygenase³⁷.
34
35
36
37
38
39
40
41
42
43
44

45 Increasing the concentration of hemin in the growth media leads to an increase in cellular
46 RH (Figure 4C) until it reaches saturation at 2 μ M hemin. The induction of heme oxygenase
47 could also contribute to the plateau in RH. Furthermore, inhibiting heme synthesis by NMP
48 causes rapid decline in RH, which within 24 hr reaches a plateau at about 30 % of the control
49 level (Figure 4B). Inhibiting heme synthesis has little effect on total heme (Figure 4A,B). The
50 slow turnover of heme-proteins could, in part, explain the resistance of total heme-proteins to
51 inhibition of heme synthesis by NMP. The positive (adding hemin) and negative (using NMP)
52 control experiments provide validation for the ability of the RH assay to detect intracellular RH.
53
54
55
56
57
58
59
60

1
2
3 They also show that RH is dynamic and its intracellular level changes on a time scale of minutes
4 (Figure 4B,C). The data also suggests that RH is independent from total heme-proteins (Figure
5 4A,B).
6
7

8
9 The toxic heavy metals Hg and Pb inhibit heme synthesis³⁸. We treated IMR90 cells with
10 subtoxic concentrations of Hg and Pb for only 24 hr in order to avoid the complications of cell
11 death. The concentrations of Pb or Hg that decrease RH are much lower than the cytotoxic
12 concentrations for both metals as experiments on fibroblasts and other cell types showed³⁹. Pb
13 causes significant decline of 26%, 34%, and 40% in RH at concentrations of 750, 1000, and 5000
14 nM, respectively (Figure 5B). Similarly, Hg causes a 20-23% decline in RH at concentrations
15 higher than 500 nM (Figure 5D). The decrease in RH by Pb or Hg reaches a plateau (Figure 5B,
16 D). One possible explanation for the plateau is that RH is a negative regulator of the heme
17 synthetic pathway. RH blocks the import of ALAS into the mitochondria, which is a key step in
18 the induction of heme synthesis¹¹. Thus, a decline in RH by Hg and Pb could induce heme
19 synthesis by increasing ALAS import into the mitochondria¹¹, preventing a further decrease in
20 RH.
21
22

23
24 Interestingly, total heme-proteins appear more resistant to Pb and Hg (Figures 5A,C).
25 These observations also suggest that the impact of treatment with Hg and Pb on RH is more
26 pronounced on RH than on total heme-proteins. Pb inhibits ALAD^{38a}, the second enzyme in
27 heme synthetic pathway, while Hg oxidizes specific SH groups in specific enzymes (such as
28 ferrochelatase), thus altering their activity^{28b, 40}. RH seems more susceptible to Pb (Figure 5B)
29 than to Hg (Figure 5D) probably due to the strong inhibition of ALAD by Pb. The effect of Hg
30 and Pb on heme synthesis, may explain in part the fast decline in RH by Pb and Hg, as compared
31 to total heme-proteins. The relative resistance of total heme-proteins to Hg and Pb (as is the case
32 with NMP) could be due to the slow rate of turnover of heme-proteins, which maybe measured
33 in days.
34
35

36
37 The neurotoxic A β peptide possesses a specific motif that tightly binds with heme to
38 form the complex A β -heme^{21, 28a, 41}. Since A β peptide readily penetrates the cell^{32b, 33, 42}, we
39 investigated the effect of A β on RH. Within 8 hr of treatment, A β caused a 60% decline in RH
40 (Figure 6). The decrease in RH could explain in part the induction of heme synthesis and the
41 increase in iron uptake that is induced by A β ^{28a, 43}. Total heme, on the other hand, was not
42 affected by A β (Figure 6B). Since A β -heme exhibits a weak peroxidase-like activity^{41, 43}, we
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 examined if A β and A β -heme interfere with the RH assay and found no effect of either form of
4 A β on the RH assay in cell-free system (data not shown). A possible explanation for the lack of
5 interference of the peroxidase activity of A β -heme on RH assay could be that the peroxidase
6 activity of A β -heme as compared to HRP is very weak⁴³.
7
8
9

10
11 Apomyoglobin reconstitutes with hemin or exchangeable heme in a cell-free system to
12 form myoglobin^{25,44}. Myoglobin is then measured at 410 nm, 600 nm, or full spectra. However,
13 the apomyoglobin approach to measure RH in cellular lysate is limited since it relies on an
14 endpoint absorbance at 410 nm, 600 nm, or full spectra. Furthermore, the use of apomyoglobin
15 in lysate would require the separation of the resulting myoglobin from the lysate proteins in
16 order to accurately measure the “free/exchangeable” heme. This requires additional protein
17 isolation procedures. These limitations make the apomyoglobin approach less sensitive, a subject
18 to interference from existing heme-proteins in the lysate, and labor intensive. The apoHRP assay,
19 on the other hand, is based on the catalytic activity of the holoperoxidase. The holoperoxidase
20 propagates the signal, thus enhancing the sensitivity (fmole) of the assay. Furthermore, the high
21 sensitivity and specificity of the apoHRP assay allow the use of a small amount of the biological
22 material. Therefore, the apoHRP assay can be used in biological samples.
23
24
25
26
27
28
29
30
31

32
33 Additional research is needed to further our understanding of the cell biology and the
34 biophysical nature of RH. All types of cells synthesize heme (except mature RBC) in order to
35 provide the prosthetic group for heme-proteins as well as RH. The RH assay we described here
36 has the potential to serve as a tool to investigate the various aspects of the cell biology and
37 biochemistry of RH in both eukaryotic as well as prokaryotic cells.
38
39
40
41
42

43 **Acknowledgment:**

44 This project was supported in part by the National Institute of Aging of NIH (R15AG041414)
45 and the American Federation for Aging Research (AFAR) to HA. We thank and acknowledge
46 Jeanette Macky and Kristen Cantarella for their technical support. The author has no conflict of
47 interest with the data presented in this study.
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1: Outline of the steps and the reagents for performing the RH assay.

Reagent	fmole, Hemin							Sample ⁵ (μ l)
	0	25	50	100	150	200	250	
1- PBS ¹ (μ l)	25	25	25	25	25	25	25	25
2- Lysate ² (μ l)	0	0	0	0	0	0	0	3-5
3- ApoHRP ³ (μ l)	10	10	10	10	10	10	10	10
4- Hemin ⁴ (μ l)	0	1	2	4	6	8	10	0
5- PBS ¹ (μ l)	65	64	63	61	59	57	55	60-62
6- Final volume ⁶ (μ l)	100	100	100	100	100	100	100	100
ApoHRP/Hemin	--	2×10^4	1×10^4	5×10^3	3.3×10^3	2.5×10^3	2×10^3	--

¹ PBS can be replaced by 80 mM KCl; 20 mM sodium phosphate, and 20 mM HEPES at a pH 7.

² The optimal range of lysate's protein concentration is less than 40 μ g.

³ apoHRP working solution is 50 μ M.

⁴ Hemin working solution is 25 nM hemin. It can be prepared in NANOpure water or 50% DMSO.

⁵ Background was measured by replacing apoHRP with PBS.

⁶ Usually 30 μ l are taken into 200 μ l TMB working solution to assay holoHRP activity.

Table 2: The levels of total heme and regulatory heme in IMR90 cells.

The intracellular level of regulatory heme (RH) and total non-covalently bound heme (TH) in human fibroblasts (IMR90) were measured by the RH assay and HPLC, respectively. The data from the controls of the many experiments (at least 13 different experiments) was combined to calculate the averages of total heme and RH in IMR90 cells. The Mann Whitney statistical test was used to analyze the data. ($P < 0.0001$).

	Mean	Std. Deviation
Total heme	67.35	14.68
Regulatory heme	4.288	1.522

Legends:**Figure 1: The time and the dose-dependent reconstitutions of apoHRP with hemin.**

ApoHRP was mixed with hemin in PBS at final concentrations of 5 μ M and 2.5 nM, respectively, as described in Table 1. At different time points a sample was removed and the resulting enzymatic activity of holoHRP was measured using the TMB assay kit and presented as absorbance at 652 nm. (A) The time-dependent reconstitution of apoHRP with hemin. The resulting absorbance at 652 nm from holoHRP activity was plotted against the reconstitution time (min) using one-binding site hyperbola (Prism 6.0 software, GraphPad, San Diego, CA, USA). The data are the mean \pm sem of four different experiments. (B) The dose-dependent reconstitution of apoHRP with increasing concentrations of hemin. ApoHRP (5 μ M) was mixed with increasing concentrations of hemin (0-2.5 nM) in PBS as described in Table 1. The resulting activity of holoHRP was measured using the TMB assay kit and the absorbance at 652 nm was plotted against the respective concentration of hemin. Linear regression analysis of the data shows $R^2 = 0.98$ (Prism 6.0 software, GraphPad, San Diego, CA, USA). The data are the mean \pm SD of triplicates of the representative experiment.

Figure 2: The time-dependent reconstitution of apoHRP with specific housekeeping heme-proteins.

The transfer of the heme moiety of hemoglobin (60 nM), methemoglobin (60 nM), catalase (60 nM), or heme proteins from the lysate (10 μ g) to apoHRP was investigated using the RH assay as described in Table 1, except hemin was replaced with the respective heme-protein as described in the Methods section. The resulting enzymatic activity of holoHRP was measured using the TMB assay kit. HoloHRP activity (as absorbance at 652 nm) was plotted against the reconstitution time using one-binding site hyperbola (Prism 6.0 software, GraphPad, San Diego, CA, USA). (A) MetHb (Closed circles, - sodium dithionite), hemoglobin (Hb-O₂, Open circles, + sodium dithionite); (B) Catalase; and (C) heme-proteins from cell-free lysate. Shown the mean \pm sem of at least three different experiments for each condition.

Figure 3: The dependence of the RH assay on apoHRP and protein concentrations.

(A) Increasing concentrations of apoHRP (0.5 to 6 μ M) were incubated with 10 μ g protein from the cell-free lysate for 10 min. The resulting holoHRP activity at 652 nM was converted to RH

1
2
3 content using standard curve similar to the one described in figure 1B. The data was plotted
4 against apoHRP concentration (Prism 6.0 software, GraphPad, San Diego, CA, USA). (B)
5 Different protein concentrations (5-60 μg) from lysate were mixed with 5 μM apoHRP for 10
6 min. The resulting holoHRP activity was converted to RH concentration using a standard curve
7 similar to the one presented in Figure 1B and as described in Materials and Methods. The
8 calculated RH/mg protein was then plotted against the protein concentration using linear
9 regression (Prism 6.0 software, GraphPad, San Diego, CA, USA). Shown the mean \pm sem of
10 four different experiments for A and B.
11
12
13
14
15
16
17
18
19

20 **Figure 4: The effect of inhibiting heme synthesis or adding hemin to the growth medium on**
21 **intracellular RH.**

22
23 The time-dependent effect (0.5 to 72 hr) of inhibiting heme synthesis with 8 μM N-methyl
24 protoporphyrin IX (NMP) on RH and total heme was determined in the cellular lysate using
25 HPLC as described in Table 1 and the Methods. (A) Shows the linear regression analysis of the
26 effect of NMP on total heme. (B) Shows the plot of the effect of NMP on RH using best-fit one-
27 phase exponential decay. The data are the mean \pm sem of three independent experiments.
28 * $P < 0.01$, ** $P < 0.001$, *** $p < 0.0001$, One-way ANOVA test using Dunnett's multiple
29 comparisons. (C) The dose-dependent effect of adding hemin (0.5 to 6 μM) to the growth
30 medium of IMR90 cell culture for 45 min. After washing hemin, the cells were harvested, the
31 lysate was prepared, and the RH content was measured as described Materials and Methods.
32 ** $P < 0.001$, One-way ANOVA test using Dunnett's multiple comparisons. Shown is the mean \pm
33 sem of three independent experiments.
34
35
36
37
38
39
40
41
42
43

44 **Figure 5: The effect of lead and mercury on regulatory and total heme.**

45
46 IMR90 cell cultures were incubated for 24 hr with increasing concentrations of Pb (250 to
47 1000nM) or Hg (0.5 to 5000nM). The cells were harvested and the lysates were prepared from
48 each condition. Total heme from lead-treated cells (A) or mercury-treated cells (C) were
49 measured by HPLC as described in Materials and Methods. RH was measured using the lysates
50 by the RH assay in lead (B) or mercury (D) treated cells. * $P < 0.01$, ** $P < 0.001$, *** $p < 0.0001$,
51 One-way ANOVA using Dunnett's multiple comparisons. Data are mean \pm sem of at least six
52 independent experiments.
53
54
55
56
57
58
59
60

1
2
3
4
5 **Figure 6: The effect of Amyloid- β ($A\beta$) peptide on regulatory and total heme.**
6

7 IMR90 cell cultures were incubated with 500 nM $A\beta_{40}$. At different time points (0.5 to 24 hr) the
8 cells were then harvested, lysates prepared, and RH and total heme were measured by the RH
9 assay and HPLC, respectively. (A) Nonlinear regression analysis of the time-dependent effect of
10 $A\beta$ on RH (one-phase exponential decay) (Prism 6.0 software, GraphPad, San Diego, CA, USA).
11 * $p < 0.01$, ** $p < 0.001$, One-way ANOVA using Dunn's multiple comparisons. The data are the
12 mean \pm sem of four independent experiments. (B) The time-dependent effect of $A\beta$ on total
13 heme. No statistical significance was observed. Data was plotted using linear regression
14 ($R^2 = 0.02$). The data are the mean \pm sem of at least three independent experiments.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References:

1. L. J. Smith, A. Kahraman, J. M. Thornton, Heme proteins--diversity in structural characteristics, function, and folding. *Proteins* 2010, *78*. 2349-68, DOI: 10.1002/prot.22747.
2. M. Paoli, J. Marles-Wright, A. Smith, Structure-function relationships in heme-proteins. *DNA Cell Biol* 2002, *21*. 271-80.
3. R. S. Ajioka, J. D. Phillips, J. P. Kushner, Biosynthesis of heme in mammals. *Biochim Biophys Acta* 2006, *1763*. 723-36.
4. W. T. Morgan, H. H. Liem, R. P. Sutor, U. Muller-Eberhard, Transfer of heme from heme-albumin to hemopexin. *Biochim Biophys Acta* 1976, *444*. 435-45.
5. (a) H. M. Girvan, A. W. Munro, Heme sensor proteins. *J Biol Chem* 2013, *288*. 13194-203, DOI: 10.1074/jbc.R112.422642; (b) U. Liebl, J. C. Lambry, M. H. Vos, Primary processes in heme-based sensor proteins. *Biochim Biophys Acta* 2013, *1834*. 1684-92, DOI: 10.1016/j.bbapap.2013.02.025.
6. (a) A. S. Tsiftoglou, A. I. Tsamadou, L. C. Papadopoulou, Heme as key regulator of major mammalian cellular functions: molecular, cellular, and pharmacological aspects. *Pharmacol Ther* 2006, *111*. 327-45; (b) L. Zhang, L. Guarente, Heme binds to a short sequence that serves a regulatory function in diverse proteins. *Embo J* 1995, *14*. 313-20; (c) A. G. Smith, E. L. Raven, T. Chernova, The regulatory role of heme in neurons. *Metallomics : integrated biometal science* 2011, *3*. 955-62, DOI: 10.1039/c1mt00085c; (d) M. A. Correia, P. R. Sinclair, F. De Matteis, Cytochrome P450 regulation: the interplay between its heme and apoprotein moieties in synthesis, assembly, repair, and disposal. *Drug Metab Rev* 2011, *43*. 1-26, DOI: 10.3109/03602532.2010.515222.
7. (a) K. Furuyama, K. Kaneko, P. D. Vargas, Heme as a magnificent molecule with multiple missions: heme determines its own fate and governs cellular homeostasis. *The Tohoku journal of experimental medicine* 2007, *213*. 1-16; (b) M. Miksanova, J. Igarashi, M. Minami, I. Sagami, S. Yamauchi, H. Kurokawa, T. Shimizu, Characterization of heme-regulated eIF2alpha kinase: roles of the N-terminal domain in the oligomeric state, heme binding, catalysis, and inhibition. *Biochemistry* 2006, *45*. 9894-905, DOI: 10.1021/bi060556k; (c) T. Kuhl, A. Wissbrock, N. Goradia, N. Sahoo, K. Galler, U. Neugebauer, J. Popp, S. H. Heinemann, O. Ohlenschlager, D. Imhof, Analysis of Fe(III) heme binding to cysteine-containing heme-regulatory motifs in proteins. *ACS chemical biology* 2013, *8*. 1785-93, DOI: 10.1021/cb400317x.
8. S. Sassa, T. Nagai, The role of heme in gene expression. *Int J Hematol* 1996, *63*. 167-78.
9. N. Gupta, S. W. Ragsdale, Thiol-disulfide redox dependence of heme binding and heme ligand switching in nuclear hormone receptor rev-erb{beta}. *J Biol Chem* 2011, *286*. 4392-403, DOI: 10.1074/jbc.M110.193466.
10. T. Hon, A. Hach, H. C. Lee, T. Cheng, L. Zhang, Functional analysis of heme regulatory elements of the transcriptional activator Hap1. *Biochem Biophys Res Commun* 2000, *273*. 584-91.
11. B. J. Goodfellow, J. S. Dias, G. C. Ferreira, P. Henklein, V. Wray, A. L. Macedo, The solution structure and heme binding of the presequence of murine 5-aminolevulinic synthase. *FEBS Lett* 2001, *505*. 325-31.
12. C. Dycke, C. Bougault, J. Gaillard, J. P. Andrieu, K. Pantopoulos, J. M. Moulis, Human iron regulatory protein 2 is easily cleaved in its specific domain: consequences for the haem binding properties of the protein. *The Biochemical journal* 2007, *408*. 429-39, DOI: 10.1042/BJ20070983.
13. S. Y. Hwang, M. K. Kim, J. C. Kim, Cloning of hHRI, human heme-regulated eukaryotic initiation factor 2alpha kinase: down-regulated in epithelial ovarian cancers. *Mol Cells* 2000, *10*. 584-91.
14. M. Faller, M. Matsunaga, S. Yin, J. A. Loo, F. Guo, Heme is involved in microRNA processing. *Nat Struct Mol Biol* 2007, *14*. 23-9.
15. (a) S. Dhakshinamoorthy, A. K. Jain, D. A. Bloom, A. K. Jaiswal, Bach1 Competes with Nrf2 Leading to Negative Regulation of the Antioxidant Response Element (ARE)-mediated NAD(P)H:Quinone Oxidoreductase 1 Gene Expression and Induction in Response to Antioxidants. *J Biol Chem* 2005, *280*. 16891-900; (b) H. Suzuki, S. Tashiro, S. Hira, J. Sun, C. Yamazaki, Y. Zenke, M. Ikeda-Saito, M. Yoshida, K. Igarashi, Heme regulates gene expression by triggering Crml-dependent nuclear export of Bach1. *Embo J* 2004, *23*. 2544-53.
16. S. Sassa, Why heme needs to be degraded to iron, biliverdin IXalpha, and carbon monoxide? *Antioxid Redox Signal* 2004, *6*. 819-24.
17. (a) T. Masuda, S. Takahashi, Chemiluminescent-based method for heme determination by reconstitution with horseradish peroxidase apo-enzyme. *Analytical biochemistry* 2006, *355*. 307-9, DOI: 10.1016/j.ab.2006.04.008; (b) J. Thomas, J. D. Weinstein, Measurement of heme efflux and heme content in isolated developing chloroplasts. *Plant physiology* 1990, *94*. 1414-23.

18. H. Atamna, A. Paler-Martinez, B. N. Ames, N-t-butyl hydroxylamine, a hydrolysis product of alpha-phenyl-N-t-butyl nitron, is more potent in delaying senescence in human lung fibroblasts. *J Biol Chem* 2000, 275. 6741-8.
19. M. L. Anson, A. E. Mirsky, Protein Coagulation and Its Reversal : The Preparation of Insoluble Globin, Soluble Globin and Heme. *The Journal of general physiology* 1930, 13. 469-76.
20. M. Tamura, T. Asakura, T. Yonetani, Heme-modification studies on horseradish peroxidase. *Biochim Biophys Acta* 1972, 268. 292-304.
21. H. Atamna, W. H. Frey, 2nd, A role for heme in Alzheimer's disease: heme binds amyloid beta and has altered metabolism. *Proc Natl Acad Sci U S A* 2004, 101. 11153-8, DOI: 10.1073/pnas.0404349101 0404349101 [pii].
22. P. D. Josephy, T. Eling, R. P. Mason, The horseradish peroxidase-catalyzed oxidation of 3,5,3',5'-tetramethylbenzidine. Free radical and charge-transfer complex intermediates. *J Biol Chem* 1982, 257. 3669-75.
23. F. E. Robles, S. Chowdhury, A. Wax, Assessing hemoglobin concentration using spectroscopic optical coherence tomography for feasibility of tissue diagnostics. *Biomed Opt Express* 2010, 1. 310-317, DOI: 10.1364/boe.1.000310/.
24. A. Deisseroth, A. L. Dounce, Catalase: Physical and chemical properties, mechanism of catalysis, and physiological role. *Physiol Rev* 1970, 50. 319-75.
25. M. S. Hargrove, E. W. Singleton, M. L. Quillin, L. A. Ortiz, G. N. Phillips, Jr., J. S. Olson, A. J. Mathews, His64(E7)-->Tyr apomyoglobin as a reagent for measuring rates of heme dissociation. *J Biol Chem* 1994, 269. 4207-14.
26. (a) J. Hardy, D. J. Selkoe, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science* 2002, 297. 353-6, DOI: 10.1126/science.1072994; (b) S. P. Cole, G. S. Marks, Ferrochelatase and N-alkylated porphyrins. *Molecular and cellular biochemistry* 1984, 64. 127-37; (c) F. De Matteis, G. S. Marks, The effect of N-methylprotoporphyrin and succinyl-acetone on the regulation of heme biosynthesis in chicken hepatocytes in culture. *FEBS letters* 1983, 159. 127-31.
27. H. Atamna, J. Liu, B. N. Ames, Heme deficiency selectively interrupts assembly of mitochondrial complex IV in human fibroblasts: relevance to aging. *J Biol Chem* 2001, 276. 48410-6.
28. (a) H. Atamna, K. Boyle, Amyloid-beta peptide binds with heme to form a peroxidase: relationship to the cytopathologies of Alzheimer's disease. *Proc Natl Acad Sci U S A* 2006, 103. 3381-6, DOI: 0600134103 [pii] 10.1073/pnas.0600134103; (b) H. A. Dailey, Metal inhibition of ferrochelatase. *Ann N Y Acad Sci* 1987, 514. 81-6.
29. S. B. Brown, H. Hatzikonstantinou, D. G. Herries, The dimerization of ferrihaems. I. The effect of buffer ions and specific cations on deuteroferrihaem dimerization. *Biochim Biophys Acta* 1978, 539. 338-51.
30. (a) B. R. Jasny, L. M. Pfeffer, I. Tamm, Effects of beta interferon on human fibroblasts at different population doubling levels. Proliferation, cell volume, thymidine uptake, and DNA synthesis. *The Journal of experimental medicine* 1984, 159. 1741-9; (b) Y. Mitsui, E. L. Schneider, Relationship between cell replication and volume in senescent human diploid fibroblasts. *Mechanisms of ageing and development* 1976, 5. 45-56; (c) B. D. Uhal, C. Ramos, I. Joshi, A. Bifero, A. Pardo, M. Selman, Cell size, cell cycle, and alpha-smooth muscle actin expression by primary human lung fibroblasts. *The American journal of physiology* 1998, 275. L998-L1005.
31. U. Moran, R. Phillips, R. Milo, SnapShot: key numbers in biology. *Cell* 2010, 141. 1262-1262 e1, DOI: 10.1016/j.cell.2010.06.019.
32. (a) T. E. Golde, C. Janus, Homing in on intracellular Abeta? *Neuron* 2005, 45. 639-42; (b) C. A. Hansson Petersen, N. Alikhani, H. Behbahani, B. Wiehager, P. F. Pavlov, I. Alafuzoff, V. Leinonen, A. Ito, B. Winblad, E. Glaser, M. Ankarcona, The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. *Proc Natl Acad Sci U S A* 2008, 105. 13145-50, DOI: 0806192105 [pii] 10.1073/pnas.0806192105.
33. (a) X. Hu, S. L. Crick, G. Bu, C. Frieden, R. V. Pappu, J. M. Lee, Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide. *Proc Natl Acad Sci U S A* 2009, 106. 20324-9, DOI: 10.1073/pnas.0911281106; (b) K. K. Kandimalla, O. G. Scott, S. Fulzele, M. W. Davidson, J. F. Poduslo, Mechanism of neuronal versus endothelial cell uptake of Alzheimer's disease amyloid beta protein. *PLoS One* 2009, 4. e4627, DOI: 10.1371/journal.pone.0004627.
34. M. S. Hargrove, D. Barrick, J. S. Olson, The association rate constant for heme binding to globin is independent of protein structure. *Biochemistry* 1996, 35. 11293-9.
35. L. Fruk, J. Kuhlmann, C. M. Niemeyer, Analysis of heme-reconstitution of apoenzymes by means of surface plasmon resonance. *Chemical communications* 2009. 230-2, DOI: 10.1039/b817206d.
36. (a) P. Krishnamurthy, T. Xie, J. D. Schuetz, The role of transporters in cellular heme and porphyrin homeostasis. *Pharmacol Ther* 2007, 114. 345-58; (b) A. A. Khan, J. G. Quigley, Heme and FLVCR-related

- transporter families SLC48 and SLC49. *Molecular aspects of medicine* 2013, 34. 669-82, DOI: 10.1016/j.mam.2012.07.013.
37. M. D. Maines, The heme oxygenase system and its functions in the brain. *Cell Mol Biol (Noisy-le-grand)* 2000, 46. 573-85.
38. (a) A. Bernard, R. Lauwerys, Metal-induced alterations of delta-aminolevulinic acid dehydratase. *Ann N Y Acad Sci* 1987, 514. 41-7; (b) W. E. Daniell, H. L. Stockbridge, R. F. Labbe, J. S. Woods, K. E. Anderson, D. M. Bissell, J. R. Bloomer, R. D. Ellefson, M. R. Moore, C. A. Pierach, W. E. Schreiber, A. Tefferi, G. M. Franklin, Environmental chemical exposures and disturbances of heme synthesis. *Environ Health Perspect* 1997, 105 Suppl 1. 37-53; (c) J. Gailer, Probing the bioinorganic chemistry of toxic metals in the mammalian bloodstream to advance human health. *Journal of inorganic biochemistry* 2012, 108. 128-32, DOI: 10.1016/j.jinorgbio.2011.12.001; (d) J. K. Kern, D. A. Geier, T. Audhya, P. G. King, L. K. Sykes, M. R. Geier, Evidence of parallels between mercury intoxication and the brain pathology in autism. *Acta neurobiologiae experimentalis* 2012, 72. 113-53; (e) M. E. Sears, K. J. Kerr, R. I. Bray, Arsenic, cadmium, lead, and mercury in sweat: a systematic review. *Journal of environmental and public health* 2012, 2012. 184745, DOI: 10.1155/2012/184745.
39. (a) A. Yamamoto, R. Honma, M. Sumita, Cytotoxicity evaluation of 43 metal salts using murine fibroblasts and osteoblastic cells. *Journal of biomedical materials research* 1998, 39. 331-40; (b) M. C. Dominguez, E. Sole, C. Goni, A. Ballabriga, Effect of aluminum and lead salts on lipid peroxidation and cell survival in human skin fibroblasts. *Biological trace element research* 1995, 47. 57-67, DOI: 10.1007/BF02790101; (c) Y. S. Hwua, J. L. Yang, Effect of 3-aminotriazole on anchorage independence and mutagenicity in cadmium- and lead-treated diploid human fibroblasts. *Carcinogenesis* 1998, 19. 881-8; (d) H. H. Bohets, M. N. Van Thielen, I. Van der Biest, G. F. Van Landeghem, P. C. D'Haese, E. J. Nouwen, M. E. De Broe, P. J. Dierickx, Cytotoxicity of mercury compounds in LLC-PK1, MDCK and human proximal tubular cells. *Kidney international* 1995, 47. 395-403.
40. T. W. Clarkson, The toxicology of mercury. *Critical reviews in clinical laboratory sciences* 1997, 34. 369-403, DOI: 10.3109/10408369708998098.
41. H. Atamna, W. H. Frey, 2nd, N. Ko, Human and rodent amyloid-beta peptides differentially bind heme: relevance to the human susceptibility to Alzheimer's disease. *Arch Biochem Biophys* 2009, 487. 59-65, DOI: S0003-9861(09)00149-0 [pii] 10.1016/j.abb.2009.05.003.
42. (a) A. Y. Lai, J. McLaurin, Mechanisms of amyloid-Beta Peptide uptake by neurons: the role of lipid rafts and lipid raft-associated proteins. *International journal of Alzheimer's disease* 2010, 2011. 548380, DOI: 10.4061/2011/548380; (b) L. B. Ravi, S. Poosala, D. Ahn, F. J. Chrest, E. L. Spangler, R. Jayakumar, E. Nagababu, J. G. Mohanty, M. Talan, D. K. Ingram, J. M. Rifkind, Red cell interactions with amyloid-beta(1-40) fibrils in a murine model. *Neurobiol Dis* 2005, 19. 28-37; (c) F. M. LaFerla, K. N. Green, S. Oddo, Intracellular amyloid-beta in Alzheimer's disease. *Nature reviews. Neuroscience* 2007, 8. 499-509, DOI: 10.1038/nrn2168; (d) R. G. Nagele, M. R. D'Andrea, W. J. Anderson, H. Y. Wang, Intracellular accumulation of beta-amyloid(1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer's disease. *Neuroscience* 2002, 110. 199-211.
43. H. Atamna, Heme binding to Amyloid-beta peptide: mechanistic role in Alzheimer's disease. *J Alzheimers Dis* 2006, 10. 255-66.
44. D. A. Simmons, L. Konermann, Characterization of transient protein folding intermediates during myoglobin reconstitution by time-resolved electrospray mass spectrometry with on-line isotopic pulse labeling. *Biochemistry* 2002, 41. 1906-14.

Figure 1A




Figure 1B




Figure 2A




Figure 2B




Figure 2C




Figure 3A




Figure 3B





Figure 4A



Metallomics Accepted Manuscript

Figure 4B




Figure 4C






Figure 5A



Metallomics Accepted Manuscript

Figure 5B



Metallomics Accepted Manuscript

Figure 5C




Figure 5D




Figure 6A




Figure 6B

